Deciphera Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2016 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Deciphera Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2016 to Q1 2024.
  • Deciphera Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$45.1M, a 9.12% increase year-over-year.
  • Deciphera Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$190M, a 4.8% decline year-over-year.
  • Deciphera Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$195M, a 8.93% decline from 2022.
  • Deciphera Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$179M, a 40.3% increase from 2021.
  • Deciphera Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$300M, a 12.6% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$190M -$45.1M +$4.53M +9.12% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 -$195M -$47.1M -$1.21M -2.64% Oct 1, 2023 Dec 31, 2023 10-Q 2024-05-10
Q3 2023 -$194M -$49.6M -$6.54M -15.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-10-30
Q2 2023 -$187M -$48.6M -$5.5M -12.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 -$182M -$49.6M -$2.72M -5.79% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 -$179M -$45.9M +$42.5M +48% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-07
Q3 2022 -$221M -$43M +$36.8M +46.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-30
Q2 2022 -$258M -$43.1M +$27.4M +38.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$286M -$46.9M +$14.4M +23.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 -$300M -$88.4M -$25.7M -40.9% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-07
Q3 2021 -$274M -$79.8M -$16.1M -25.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$258M -$70.4M -$3.19M -4.75% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$255M -$61.3M +$11.5M +15.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$266M -$62.7M +$4.48M +6.66% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-09
Q3 2020 -$271M -$63.7M -$7.51M -13.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$263M -$67.2M -$45.8M -213% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$218M -$72.8M -$25.4M -53.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 -$192M -$67.2M -$34.9M -108% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-09
Q3 2019 -$157M -$56.2M -$31.8M -130% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-09
Q2 2019 -$126M -$21.5M +$230K +1.06% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-09
Q1 2019 -$126M -$47.4M -$26M -121% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-09
Q4 2018 -$99.9M -$32.3M -$12.4M -62.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 -$87.5M -$24.4M -$12.4M -103% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-09
Q2 2018 -$75.1M -$21.7M -$11.1M -104% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-09
Q1 2018 -$64M -$21.4M -$13.7M -178% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-09
Q4 2017 -$50.3M -$19.9M -$11.4M -133% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$38.9M -$12M -$5.94M -97.4% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 -$33M -$10.6M -$4.69M -79.1% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 -$28.3M -$7.71M -$2.36M -44% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
Q4 2016 -$25.9M -$8.56M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-28
Q3 2016 -$6.1M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-28
Q2 2016 -$5.93M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-28
Q1 2016 -$5.35M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.